Clearmind Medicine
Treatments for Binge Behavior and Mental Health
Startup Public Health Tech & Life Sciences Est. 2021
🌐 WebsiteLinkedInTwitter
Total Raised
$15.65M
Public
Last Round
$2.4M
5 rounds
Investors
1
1 public
Team
2
1-10 employees
Confidence
92/100
News
148
articles
Patents
1
About
Clearmind Medicine develops treatments for binge behavior and mental health, including alcohol use disorder, binge eating and depression. Clearmind develops MEAI that exerts a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages with potential to change the lives of millions who struggle to drink in moderation.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
BiologicalsMolecules
Target Customer
Healthcare & Life SciencesHealthcareLaboratories
Business Model
B2B
Tags
drug-discoverymental-healthpharmaceuticals
Funding & Events
Sep 2023
Exit Undisclosed
Nov 2022
Exit Undisclosed
Jun 2022
Exit Undisclosed
Jan 2024
PIPE $2.4M
Undisclosed Investor(s)
Apr 2023
Exit Undisclosed
News (148)
Oct 31, 2025 · finance.yahoo.com
growth-positive
Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
Product StagePublic Trading
Oct 30, 2025 · finance.yahoo.com
growth-positive
Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Product StageFDA approved/pending approval
Oct 28, 2025 · finance.yahoo.com
growth-positive
Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar
Product Stage
Oct 27, 2025 · finance.yahoo.com
growth-positive
Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement
Management ChangesPartnersProduct Stage
Oct 21, 2025 · finance.yahoo.com
growth-positive
Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Product StageCustomers
Sep 25, 2025 · finance.yahoo.com
growth-positive
Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies
Product StagePartners
Sep 19, 2025 · finance.yahoo.com
growth-positive
Clearmind Medicine Signs Deal to Raise Up to $10 Million Through Convertible Notes
Investment
Sep 19, 2025 · finance.yahoo.com
growth-positive
Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
Investment
Aug 7, 2025 · finance.yahoo.com
growth-positive
Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
Product StagePartners
Aug 7, 2025 · finance.yahoo.com
growth-positive
SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
Product StagePartners
Aug 5, 2025 · finance.yahoo.com
growth-positive
Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
Product StageFDA approved/pending approval
Jul 30, 2025 · finance.yahoo.com
growth-positive
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
Product StagePartners
Jul 30, 2025 · finance.yahoo.com
growth-positive
Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
Product StagePartners
Jul 23, 2025 · finance.yahoo.com
growth-positive
Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder
Product StageCustomersPartners
Jul 20, 2025 · finance.yahoo.com
growth-positive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Product StageExpand
Jul 15, 2025 · finance.yahoo.com
growth-positive
Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled
Product StageCustomers
Jul 9, 2025 · finance.yahoo.com
growth-positive
Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck
Product StagePartners
Jul 3, 2025 · finance.yahoo.com
Sector Update: Health Care Stocks Mixed Thursday Afternoon
Jul 3, 2025 · finance.yahoo.com
growth-positive
Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center
Product StageFDA approved/pending approval
Jun 30, 2025 · finance.yahoo.com
growth-positive
Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder
Product Stage
+ 128 more articles
Details
Product Stage
Clinical Trial
Employees
1-10
Exact Count
5
Founded
2021
Registrar
516397759
Crunchbase
clearmind-medicine
Locations
Raoul Wallenberg St 20, Tel Aviv-Yafo, Israel
1220 W 6th Ave #101, Vancouver, BC V6H 1A4, Canada
Links
Website
www.clearmindmedicine.com/
LinkedIn
Profile
Twitter
Profile
Facebook
Page
Admin
Last Update
Oct 31, 2025
Verified by
Yanina Wainscheinker
Missing
markets, not claimed
Team (2)
Adi Zuloff-Shani
CEO
Yael Stav
Head of Project Management
Internal
Created by
Ortal Wein (ortalw@sncentral.org)
Created
2023-06-29T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)
Status
Public on CSE on Jun, 2022;Public on NASDAQ on Nov, 2022;
Finder · Clearmind Medicine · 2026